The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 01, 2008
Filed:
Apr. 21, 2006
Maria Niewöhner, Legal Representative, Wermelskirchen, DE;
Mazen Es-sayed, Langenfeld, DE;
Helmut Haning, Wuppertal, DE;
Thomas Schenke, Bergisch Gladbach, DE;
Karl-heinz Schlemmer, Wuppertal, DE;
Jörg Keldenich, Wuppertal, DE;
Erwin Bischoff, Wuppertal, DE;
Elisabeth Perzborn, Wuppertal, DE;
Klaus Dembowsky, Boston, MA (US);
Peter Serno, Bergisch Gladbach, DE;
Marc Nowakowski, Wuppertal, DE;
Maria Niewöhner, legal representative, Wermelskirchen, DE;
Mazen Es-Sayed, Langenfeld, DE;
Helmut Haning, Wuppertal, DE;
Thomas Schenke, Bergisch Gladbach, DE;
Karl-Heinz Schlemmer, Wuppertal, DE;
Jörg Keldenich, Wuppertal, DE;
Erwin Bischoff, Wuppertal, DE;
Elisabeth Perzborn, Wuppertal, DE;
Klaus Dembowsky, Boston, MA (US);
Peter Serno, Bergisch Gladbach, DE;
Marc Nowakowski, Wuppertal, DE;
Bayer Aktiengesellschaft, Leverkusen, DE;
Abstract
The application claims a method for treating hypertension by administering an effective amount of a compound of the formula (I) wherein the variable groups are as defined in the specification and claims. These 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.